株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

B型インフルエンザ感染症:パイプライン分析

Influenza B Infections - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 243034
出版日 ページ情報 英文 71 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
B型インフルエンザ感染症:パイプライン分析 Influenza B Infections - Pipeline Review, H2 2016
出版日: 2016年07月30日 ページ情報: 英文 71 Pages
概要

B型インフルエンザは、インフルエンザウイルスのサブタイプで、散発的に発生する傾向が離ます。その症状には、鼻水、喉の痛み、筋肉の痛み、倦怠感、流涙、全身の痛み、食欲不振、脱力感などがあります。

当レポートでは、世界においてパイプライン中にあるB型インフルエンザ感染症治療薬の概要を提供しており、現在の開発パイプラインの状況や最新動向、後期段階および中止されたプロジェクトの情報、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

B型インフルエンザ感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

B型インフルエンザ感染症:企業で開発中の治療薬

B型インフルエンザ感染症:大学/機関で研究中の治療薬

B型インフルエンザ感染症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

B型インフルエンザ感染症:企業で開発中の製品

B型インフルエンザ感染症:大学/機関で研究中の製品

B型インフルエンザ感染症の治療薬開発に従事している企業

  • Altravax, Inc.
  • Aphios Corporation
  • Chimerix, Inc.
  • ContraFect Corporation
  • Crucell N.V.
  • CSL Limited
  • Genentech, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Humabs BioMed SA
  • Medicago Inc.
  • MedImmune, LLC
  • Mucosis B.V.
  • Novavax, Inc.
  • Sanofi Pasteur SA
  • Vaxart, Inc.
  • Zydus Cadila Healthcare Limited

B型インフルエンザ感染症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AL-18
  • APP-0205
  • APP-309
  • CF-403
  • CR-8033
  • CR-8071
  • CR-9114
  • FluGEM
  • インフルエンザ 血清型 B ワクチン
  • インフルエンザ 血清型 A, B (スプリットビリオン, 四価) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B/ビクトリア系 + B/山形系 (四価, スプリットビリオン) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B/山形系 + B/ビクトリア系 (四価) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B/山形系 (三価, スプリットビリオン) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B/山形系 (三価, ウイルス様粒子) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B/山形系 (三価, ウイルス様粒子) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B (四価, ウイルス様粒子) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B (三価, スプリットビリオン) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B (三価, スプリットビリオン) ワクチン
  • インフルエンザ ウィルス株の型 A/H1N1 + A/H3N2 + B (三価, スプリットビリオン) ワクチン
  • Mインフルエンザ B 感染症向けモノクローナル阻害剤
  • リン酸オセルタミビル
  • RG-6024
  • インフルエンザ B 向け小分子
  • VXABYW-10

B型インフルエンザ感染症:最近のパイプライン動向

B型インフルエンザ感染症:休止中のプロジェクト

B型インフルエンザ感染症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8313IDB

Summary

Global Markets Direct's, 'Influenza B Infections - Pipeline Review, H2 2016', provides an overview of the Influenza B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
  • The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects
  • The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Influenza B Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza B Infections Overview
  • Therapeutics Development
    • Pipeline Products for Influenza B Infections - Overview
    • Pipeline Products for Influenza B Infections - Comparative Analysis
  • Influenza B Infections - Therapeutics under Development by Companies
  • Influenza B Infections - Therapeutics under Investigation by Universities/Institutes
  • Influenza B Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Influenza B Infections - Products under Development by Companies
  • Influenza B Infections - Products under Investigation by Universities/Institutes
  • Influenza B Infections - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Altravax, Inc.
    • Aphios Corporation
    • BioClonetics Immunotherapeutics, Inc.
    • ContraFect Corporation
    • Humabs BioMed SA
    • Johnson & Johnson
    • Medicago Inc.
    • MedImmune, LLC
    • Mucosis B.V.
    • Sanofi Pasteur SA
    • Vaxart, Inc.
    • Zydus Cadila Healthcare Limited
  • Influenza B Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AL-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-0205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-8033 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-8071 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-9114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fluad (quadrivalent) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FluGEM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [serotypes A, B] (split virion, tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Influenza B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Influenza B Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VXABYW-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenza B Infections - Dormant Projects
  • Influenza B Infections - Discontinued Products
  • Influenza B Infections - Product Development Milestones
    • Featured News & Press Releases
      • Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial
      • Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine
      • Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Influenza B Infections, H2 2016
  • Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Influenza B Infections - Pipeline by AbbVie Inc., H2 2016
  • Influenza B Infections - Pipeline by Altravax, Inc., H2 2016
  • Influenza B Infections - Pipeline by Aphios Corporation, H2 2016
  • Influenza B Infections - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016
  • Influenza B Infections - Pipeline by ContraFect Corporation, H2 2016
  • Influenza B Infections - Pipeline by Humabs BioMed SA, H2 2016
  • Influenza B Infections - Pipeline by Johnson & Johnson, H2 2016
  • Influenza B Infections - Pipeline by Medicago Inc., H2 2016
  • Influenza B Infections - Pipeline by MedImmune, LLC, H2 2016
  • Influenza B Infections - Pipeline by Mucosis B.V., H2 2016
  • Influenza B Infections - Pipeline by Sanofi Pasteur SA, H2 2016
  • Influenza B Infections - Pipeline by Vaxart, Inc., H2 2016
  • Influenza B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Influenza B Infections - Dormant Projects, H2 2016
  • Influenza B Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Influenza B Infections, H2 2016
  • Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top